Answers are grounded in this paper and cite their sources.
Rabbit anti-T-lymphocyte globulin (ATLG; Grafalon) and rabbit anti-thymocyte globulin (ATG; Thymoglobulin) are noninterchangeable polyclonal preparations used within haploidentical hematopoietic cell transplantation (haplo-HCT) platforms. Their immunogens, antibody repertoires and nominal dose scales differ, but direct comparative clinical evidence is sparse. This narrative review examines product-specific evidence, active-antibody exposure and the unresolved dosing of serotherapy combined with post-transplant cyclophosphamide (PTCy). The available propensity-matched haploidentical comparison used Thymoglobulin 6 mg/kg and ATLG 10 mg/kg; the latter was substantially below ATLG totals commonly used even in matched-donor transplantation. Its infection and chronic graft-versus-host disease findings therefore cannot establish intrinsic product differences. PTCy-based and serotherapy-based platforms coexist, including outside Western centers, and neither the optimal rabbit-globulin dose nor the optimal PTCy dose in combined regimens is established. Recipient absolute lymphocyte count (ALC), infusion timing and graft cellularity modify exposure. ATLG-specific ALC studies support this association, but prospectively validated ATLG ALC-based dosing models remain needed. Product, conditioning, graft source, PTCy, mycophenolate mofetil and other immunosuppression should be evaluated as one protocol. Clinical use should follow product-specific, locally validated regimens while trials define exposure targets and the net benefit of combination prophylaxis.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: